Moleculin Biotech, Inc.: H.C. Wainwright cuts target price to $3 from $22

H.C. Wainwright has revised its price target for Moleculin Biotech, Inc. (MBRX.US), reducing it from $22 to $3, reflecting a significant downward adjustment in its valuation outlook for the biotechnology firm. The move signals a shift in the firm’s assessment of Moleculin’s near-term prospects, potentially influenced by ongoing operational challenges or evolving market conditions. Investors are advised to closely monitor the company’s upcoming developments and clinical trial progress, as these factors could influence future analyst evaluations. Moleculin Biotech remains active in the biotech sector, with a focus on developing novel therapeutics, though recent analyst actions suggest caution in the short term. The updated target price does not necessarily reflect a change in the company’s long-term strategic direction but may indicate a reassessment of near-term risks and uncertainties. As always, investors should consider a range of analyst opinions and company-specific developments when making investment decisions. (revised price target)